Recently Featured

Arna Pharma and Slate Run Complete JV for New US Company

June 4, 2026
Arna Pharma and Slate Run Pharmaceuticals have finalized their joint venture to establish a new entity dedicated to the development of branded products and 505(b)(2) medicines. This strategic collaboration marks a significant step in the evolving landscape of pharmaceutical innovation, particularly in the U.S. market where the demand for flexible regulatory pathways is increasing. The…

SCOTUS Temporarily Restores Telehealth Access to Abortion Pill Mifepristone

June 4, 2026
The U.S. Supreme Court has issued an emergency order, temporarily blocking a federal appeals court ruling in Louisiana that would have restricted the prescription of the abortion pill mifepristone via telehealth and mail. This decision allows healthcare providers to continue offering remote consultations and prescriptions, maintaining access to this critical medication for patients across the…

Kyowa Kirin secures FDA approval for Crysvita dosing update

June 3, 2026
Kyowa Kirin has received FDA approval for an updated dosing regimen for Crysvita, enhancing the prescribing information for this treatment aimed at adults with X-linked hypophosphatemia (XLH). This significant regulatory milestone not only expands treatment options but also reflects the ongoing commitment to address the needs of patients suffering from this rare bone disorder. The…

As biologics dominate biopharma pipelines, manufacturing hurdles trip up new launches: report

June 3, 2026
As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity behind the manufacturing of those products is putting production and launches under pressure. A recent report highlights that while the shift towards biologics promises innovative therapies, it also introduces significant manufacturing challenges that can delay market entry. The intricate nature…

Ongoing Cases